Covered recipient · General Payments record
ALEXA M HETZEL
Physician Assistants & Advanced Practice Nursing Providers Physician Assistant
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$248,290.61
568 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $170,981.86 | 121 |
| Consulting Fee | $50,708.40 | 38 |
| Travel and Lodging | $16,701.52 | 95 |
| Food and Beverage | $7,427.76 | 306 |
| Honoraria | $2,160.00 | 3 |
| Education | $311.07 | 5 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $57,184.98 | 100 |
| UCB, Inc. | $40,229.61 | 70 |
| ABBVIE INC. | $39,793.01 | 90 |
| Janssen Biotech, Inc. | $23,278.45 | 60 |
| Arcutis Biotherapeutics, Inc. | $18,843.05 | 29 |
| Galderma Laboratories, L.P. | $15,146.59 | 37 |
| Incyte Corporation | $12,455.18 | 46 |
| PFIZER INC. | $11,067.02 | 21 |
| Eli Lilly and Company | $9,188.71 | 8 |
| GENZYME CORPORATION | $8,872.10 | 11 |
| E.R. Squibb & Sons, L.L.C. | $6,377.49 | 17 |
| LNHC, Inc | $2,160.00 | 3 |
| Amgen Inc. | $899.01 | 12 |
| LEO Pharma Inc. | $876.92 | 15 |
| Journey Medical Corporation | $565.26 | 2 |
| Kowa Pharmaceuticals America, Inc. | $400.00 | 1 |
| Novartis Pharmaceuticals Corporation | $288.65 | 12 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $272.10 | 13 |
| Regeneron Healthcare Solutions, Inc. | $247.00 | 9 |
| Organon LLC | $79.89 | 8 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $35.03 | 2 |
| Botanix SB Inc | $17.39 | 1 |
| Janssen Pharmaceuticals, Inc | $13.17 | 1 |
Page 3 of 12; records 101–150 of 568 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ALEXA M HETZEL
NPI 1851887301 · CMS profile ID 10806017
Physician Assistants & Advanced Practice Nursing Providers / Physician Assistant
EAST WINDSOR, NJ
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 12; records 101–150 of 568 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1851887301?year=2025&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ALEXA M HETZEL, NPI 1851887301, CMS profile ID 10806017. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 12; records 101–150 of 568 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1851887301?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). ALEXA M HETZEL, NPI 1851887301, CMS profile ID 10806017. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 12; records 101–150 of 568 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1851887301?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- ALEXA M HETZEL, NPI 1851887301, CMS profile ID 10806017, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 12; records 101–150 of 568 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1851887301?year=2025&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
568 matching records · $248,290.61 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 568.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Lilly USA, LLC | $575.00 | 10/23/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1187063076 | CMS |
| Organon LLC | $5.89 | 10/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1237786388 | CMS |
| ABBVIE INC. | $14.96 | 10/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1204285866 | CMS |
| Galderma Laboratories, L.P. | $2.80 | 10/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234769445 | CMS |
| LNHC, Inc | $560.00 | 10/22/2025 | Honoraria | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1242607159 | CMS |
| Novartis Pharmaceuticals Corporation | $20.82 | 10/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200243932 | CMS |
| Janssen Biotech, Inc. | $15.42 | 10/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175244451 | CMS |
| Journey Medical Corporation | $500.00 | 10/20/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250935484 | CMS |
| Galderma Laboratories, L.P. | $17.75 | 10/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234769443 | CMS |
| Incyte Corporation | $255.00 | 10/16/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226027211 | CMS |
| Incyte Corporation | $18.87 | 10/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226182069 | CMS |
| Kowa Pharmaceuticals America, Inc. | $400.00 | 10/16/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1243141643 | CMS |
| GENZYME CORPORATION | $19.63 | 10/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233656793 | CMS |
| Arcutis Biotherapeutics, Inc. | $800.00 | 10/14/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1252379917 | CMS |
| PFIZER INC. | $620.36 | 10/14/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1230471391 | CMS |
| Janssen Biotech, Inc. | $18.48 | 10/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175244382 | CMS |
| Lilly USA, LLC | $10.46 | 10/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186949063 | CMS |
| Organon LLC | $8.75 | 10/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1237786396 | CMS |
| PFIZER INC. | $2,875.00 | 10/09/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1230471395 | CMS |
| ABBVIE INC. | $3.22 | 10/08/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1204285834 | CMS |
| ABBVIE INC. | $56.00 | 10/08/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1204285839 | CMS |
| ABBVIE INC. | $10.60 | 10/08/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1204285844 | CMS |
| ABBVIE INC. | $33.60 | 10/08/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1204285849 | CMS |
| ABBVIE INC. | $4.03 | 10/08/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1204285854 | CMS |
| ABBVIE INC. | $49.00 | 10/08/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1204285860 | CMS |
| Janssen Biotech, Inc. | $27.50 | 10/08/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175244319 | CMS |
| Janssen Biotech, Inc. | $12.26 | 10/08/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175244438 | CMS |
| Janssen Biotech, Inc. | $70.70 | 10/08/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175244443 | CMS |
| Lilly USA, LLC | $3.58 | 10/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186982154 | CMS |
| E.R. Squibb & Sons, L.L.C. | $3.89 | 10/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184762276 | CMS |
| Galderma Laboratories, L.P. | $8.77 | 10/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234769441 | CMS |
| PFIZER INC. | $18.04 | 10/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1230803204 | CMS |
| Regeneron Healthcare Solutions, Inc. | $6.84 | 10/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213140470 | CMS |
| ABBVIE INC. | $12.22 | 10/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1204285828 | CMS |
| Janssen Biotech, Inc. | $2,025.00 | 10/04/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175244844 | CMS |
| Janssen Biotech, Inc. | $30.85 | 10/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175244917 | CMS |
| ABBVIE INC. | $1,500.00 | 10/02/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1204285818 | CMS |
| ABBVIE INC. | $6.51 | 10/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1204285823 | CMS |
| LEO Pharma Inc. | $19.54 | 10/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1252066409 | CMS |
| Lilly USA, LLC | $950.00 | 10/02/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186954859 | CMS |
| Lilly USA, LLC | $1,500.00 | 10/02/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186977390 | CMS |
| UCB, Inc. | $4.46 | 10/02/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224662356 | CMS |
| UCB, Inc. | $5.99 | 10/02/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224662360 | CMS |
| UCB, Inc. | $7.67 | 10/02/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224662364 | CMS |
| UCB, Inc. | $47.04 | 10/02/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224662368 | CMS |
| ABBVIE INC. | $16.00 | 10/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1204285812 | CMS |
| Janssen Biotech, Inc. | $98.50 | 10/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175245077 | CMS |
| UCB, Inc. | $3.35 | 10/01/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224662348 | CMS |
| UCB, Inc. | $3,200.00 | 10/01/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224662352 | CMS |
| Novartis Pharmaceuticals Corporation | $24.86 | 09/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200251422 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $162,358.13 | 18 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
18 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 12/25/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184280314 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,537.00 | 12/22/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surface Area | No dispute reported | 06/30/2026 | 1175432965 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,960.00 | 12/19/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175432958 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,309.00 | 12/10/2025 | Non-covered Recipient Entity Sdg Dermatology Pc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226103929 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,243.00 | 12/04/2025 | Non-covered Recipient Entity Sdg Dermatology Pc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226103903 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,824.20 | 11/14/2025 | Non-covered Recipient Entity Sdg Dermatology Pc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226103896 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,781.00 | 10/23/2025 | Non-covered Recipient Entity Schweiger Derm Group-East Windsor | A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics | No dispute reported | 06/30/2026 | 1175244320 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,981.00 | 10/22/2025 | Non-covered Recipient Entity Sdg Dermatology Pc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226103870 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,696.00 | 09/17/2025 | Non-covered Recipient Entity Sdg Dermatology Pc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226103827 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $24,706.00 | 08/20/2025 | Non-covered Recipient Entity Sdg Dermatology Pc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226103786 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,668.60 | 07/31/2025 | Non-covered Recipient Entity Schweiger Derm and Allergy-East Windsor | A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics | No dispute reported | 06/30/2026 | 1175244310 |
| Principal investigator 1 | Janssen Research & Development, LLC | $18,966.40 | 07/31/2025 | Non-covered Recipient Entity Schweiger Derm Group-East Windsor | A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics | No dispute reported | 06/30/2026 | 1175244336 |
| Principal investigator 1 | Janssen Research & Development, LLC | $45.00 | 07/31/2025 | Non-covered Recipient Entity Schweiger Derm and Allergy-East Windsor | A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics | No dispute reported | 06/30/2026 | 1175244367 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,963.50 | 07/22/2025 | Non-covered Recipient Entity Schweiger Derm and Allergy-East Windsor | A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics | No dispute reported | 06/30/2026 | 1175244328 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,327.88 | 07/22/2025 | Non-covered Recipient Entity Schweiger Derm and Allergy-East Windsor | A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics | No dispute reported | 06/30/2026 | 1175244383 |
| Principal investigator 1 | Eli Lilly and Company | $18,080.00 | 07/08/2025 | Non-covered Recipient Entity JERRY BAGEL MD LLC | A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT IN CLINICAL PRACTICE | No dispute reported | 06/30/2026 | 1187885378 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $12,500.00 | 06/13/2025 | Non-covered Recipient Entity Sdg Dermatology Pc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226103718 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,370.80 | 05/02/2025 | Non-covered Recipient Entity Schweiger Derm Group-East Windsor | A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics | No dispute reported | 06/30/2026 | 1175244396 |